FDA Approves New Pancreatic Cancer Drug Rasonque

Why it matters locally: The approval of Rasonque offers a new treatment option for patients with metastatic pancreatic cancer across Tennessee, including those receiving care at facilities like TriStar Centennial Medical Center Emergency Room in Davidson County or Memphis Regional Medical Center in Shelby County.

WASHINGTON – The U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib) today, introducing a new treatment for metastatic pancreatic cancer. Rasonque functions as a RAS inhibitor, targeting the most common form of the disease. Regulators made the approval several months ahead of their projected schedule. The decision makes Rasonque available to patients with advanced pancreatic cancer.